Helen McShane

Helen McShane in the video ''Exposed'' Helen Irene McShane is a British infectious disease physician and a professor of vaccinology in the Jenner Institute at the University of Oxford, where she has led the tuberculosis vaccine research group since 2001, and is the director of the Oxford NIHR Biomedical Research Centre. She is senior research fellow at Harris Manchester College, Oxford, and the Deputy Head of the Medical Sciences Division, University of Oxford. Provided by Wikipedia
Showing 1 - 19 results of 19 for search 'Helen McShane', query time: 0.03s Refine Results
  1. 1
    Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.

    Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy. by Angela M Minassian, Edward O Ronan, Hazel Poyntz, Adrian V S Hill, Helen McShane

    Published 2011-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.

    Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection. by Gareth Betts, Hazel Poyntz, Elena Stylianou, Arturo Reyes-Sandoval, Matthew Cottingham, Adrian Hill, Helen McShane

    Published 2012-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice.

    Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice. by Kristin L Griffiths, Elena Stylianou, Hazel C Poyntz, Gareth J Betts, Helen A Fletcher, Helen McShane

    Published 2013-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses.

    Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses. by Anna M Checkley, David H Wyllie, Thomas J Scriba, Tanya Golubchik, Adrian V S Hill, Willem A Hanekom, Helen McShane

    Published 2011-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    The tuberculin skin test (TST) is affected by recent BCG vaccination but not by exposure to non-tuberculosis mycobacteria (NTM) during early life.

    The tuberculin skin test (TST) is affected by recent BCG vaccination but not by exposure to non-tuberculosis mycobacteria (NTM) during early life. by Sarah Burl, Uche J Adetifa, Momodou Cox, Ebrima Touray, Hilton Whittle, Helen McShane, Sarah L Rowland-Jones, Katie L Flanagan

    Published 2010-08-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.

    Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. by Kathryn T Whelan, Ansar A Pathan, Clare R Sander, Helen A Fletcher, Ian Poulton, Nicola C Alder, Adrian V S Hill, Helen McShane

    Published 2009-06-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.

    Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A. by Kristin L Griffiths, Ansar A Pathan, Angela M Minassian, Clare R Sander, Natalie E R Beveridge, Adrian V S Hill, Helen A Fletcher, Helen McShane

    Published 2011-01-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.

    Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A. by Magali Matsumiya, Elena Stylianou, Kristin Griffiths, Zoe Lang, Joel Meyer, Stephanie A Harris, Rosalind Rowland, Angela M Minassian, Ansar A Pathan, Helen Fletcher, Helen McShane

    Published 2013-01-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.

    Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. by Ansar A Pathan, Clare R Sander, Helen A Fletcher, Ian Poulton, Nicola C Alder, Natalie E R Beveridge, Kathryn T Whelan, Adrian V S Hill, Helen McShane

    Published 2007-10-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations.

    Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. by Willem A Hanekom, Hazel M Dockrell, Tom H M Ottenhoff, T Mark Doherty, Helen Fletcher, Helen McShane, Frank F Weichold, Dan F Hoft, Shreemanta K Parida, Uli J Fruth

    Published 2008-07-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

    Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. by Roger H Brookes, Philip C Hill, Patrick K Owiafe, Hannah B Ibanga, David J Jeffries, Simon A Donkor, Helen A Fletcher, Abdulrahman S Hammond, Christian Lienhardt, Richard A Adegbola, Helen McShane, Adrian V S Hill

    Published 2008-08-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.

    Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects. by Tandakha N Dieye, Birahim P Ndiaye, Alle B Dieng, Marema Fall, Nathaniel Brittain, Samantha Vermaak, Makhtar Camara, Halimatou Diop-Ndiaye, Ndeye Fatou Ngom-Gueye, Papa A Diaw, Coumba Toure-Kane, Papa S Sow, Souleymane Mboup, Helen McShane

    Published 2013-01-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines.

    Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines. by Steven G Smith, Kaatje Smits, Simone A Joosten, Krista E van Meijgaarden, Iman Satti, Helen A Fletcher, Nadia Caccamo, Francesco Dieli, Francoise Mascart, Helen McShane, Hazel M Dockrell, Tom H M Ottenhoff, TBVI TB Biomarker Working Group

    Published 2015-01-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates

    MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates by Marco Polo Peralta-Álvarez, Keya Downward, Andrew White, Hugo Redondo Azema, Laura Sibley, Charlotte Sarfas, Alexandra Morrison, Mike Dennis, Delia Diaz-Santana, Stephanie A. Harris, Shuailin Li, Eugenia Puentes, Nacho Aguilo, Carlos Martin, Sally Sharpe, Helen McShane, Rachel Tanner

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    MetE: a promising protective antigen for tuberculosis vaccine development

    MetE: a promising protective antigen for tuberculosis vaccine development by Salem Salman Almujri, Salem Salman Almujri, Elena Stylianou, Annalisa Nicastri, Annalisa Nicastri, Iman Satti, Marcellus Korompis, Shuailin Li, Christopher J. De Voss, Marco Polo Peralta Alvarez, Rachel Tanner, Rachel Tanner, Paulo J. G. Bettencourt, Paulo J. G. Bettencourt, Nicola Ternette, Nicola Ternette, Helen McShane

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.

    MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. by Frank A W Verreck, Richard A W Vervenne, Ivanela Kondova, Klaas W van Kralingen, Edmond J Remarque, Gerco Braskamp, Nicole M van der Werff, Ariena Kersbergen, Tom H M Ottenhoff, Peter J Heidt, Sarah C Gilbert, Brigitte Gicquel, Adrian V S Hill, Carlos Martin, Helen McShane, Alan W Thomas

    Published 2009-01-01
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.

    A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated... by Sharon Sheehan, Stephanie A Harris, Iman Satti, David A Hokey, Veerabadran Dheenadhayalan, Lisa Stockdale, Zita-Rose Manjaly Thomas, Alice Minhinnick, Morven Wilkie, Samantha Vermaak, Joel Meyer, Matthew K O'Shea, Maria Grazia Pau, Isabella Versteege, Macaya Douoguih, Jenny Hendriks, Jerald Sadoff, Bernard Landry, Paul Moss, Helen McShane

    Published 2015-01-01
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG

    Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG by Julia L. Marshall, Iman Satti, Mirvat Surakhy, Stephanie A. Harris, Hazel Morrison, Rachel E. Wittenberg, Marco Polo Peralta Alvarez, Shuailin Li, Raquel Lopez Ramon, Emily Hoogkamer, Francsico Javier Salguero, Fernando Ramos Lopez, Celia Mitton, Ingrid Cabrera Puig, Rebecca Powell Doherty, Rachel Tanner, Timothy S. C. Hinks, Henry Bettinson, Helen McShane

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    Reducing inequalities through greater diversity in clinical trials – As important for medical devices as for drugs and therapeutics

    Reducing inequalities through greater diversity in clinical trials – As important for medical devices as for drugs and therapeutics by Laurence S.J. Roope, Jessica Walsh, Maddie Welland, Gabrielle Samuel, Heidi Johansen-Berg, Anna C. Nobre, Stuart Clare, Helen Higham, Jon Campbell, Tim Denison, Karla L. Miller, Seena Fazel, Matthew L. Costa, Andrew Farmer, Marian Knight, Rachel Taylor, Lorna R. Henderson, Angeli Vaid, John Geddes, Vasiliki Kiparoglou, Helen McShane, Philip M. Clarke

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: